Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases

Figure 3

Cell proliferation in glucose oxidase stressed ARPE-19 cells cultured with the pharmaceutical compositions (PhC). Damaged ARPE-19 cell proliferation was measured using alamarBlue® at days 1, 3, and 6 of cell culture with the PhC. (a) aMSC-CM combined (PhC 1) with NIC, VIP, or NIC+VIP tended to reduce cell proliferation of glucose oxidase stressed ARPE-19 cells. While the effect was greatest in the presence of NIC+VIP, none of the differences were significant (). (b) aMSC-CM stimulated-combined (PhC 2) and (c) aMSC-CM stimulated (PhC 3) conditions tended to have higher better proliferation rates in glucose oxidase stressed ARPE-19 cells, though again, the differences were not significant. Bars represent the mean of . Statistical analysis: repeated measures ANOVA with Tukey’s post hoc tests and Bonferroni corrections for multiple testing. Three experiments () in triplicate were performed. aMSC: adipose-derived mesenchymal stem cells; CM: conditioned medium; NIC: nicotinamide; VIP: vasoactive intestinal peptide.

(a)

(b)

(c)